OTLK FY2026 EPS Lifted by Brookline Capital Management

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Brookline Capital Management raised their FY2026 earnings estimates for shares of Outlook Therapeutics in a research report issued to clients and investors on Monday, December 30th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings of $0.65 per share for the year, up from their previous forecast of $0.61. The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($3.84) per share.

A number of other brokerages also recently issued reports on OTLK. Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. BTIG Research decreased their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Outlook Therapeutics in a report on Friday, November 29th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.73.

Outlook Therapeutics Stock Up 1.6 %

NASDAQ:OTLK opened at $1.89 on Tuesday. Outlook Therapeutics has a 52 week low of $0.87 and a 52 week high of $12.85. The stock’s fifty day moving average is $3.59 and its two-hundred day moving average is $5.77. The company has a market capitalization of $47.07 million, a P/E ratio of -0.18 and a beta of 0.46.

Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06.

Institutional Trading of Outlook Therapeutics

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC acquired a new position in Outlook Therapeutics during the 2nd quarter worth $75,000. Christensen King & Associates Investment Services Inc. acquired a new position in Outlook Therapeutics during the 3rd quarter worth approximately $55,000. Barclays PLC increased its holdings in Outlook Therapeutics by 677.4% in the third quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after buying an additional 18,249 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Outlook Therapeutics by 55.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock valued at $275,000 after acquiring an additional 18,287 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Outlook Therapeutics by 10.0% in the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after acquiring an additional 21,201 shares during the last quarter. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.